News tagged with paclitaxel
By tracking changes in patients' blood, Cambridge scientists have created a new way of looking at how tumours evolve in real-time and develop drug resistance. The research was published in the print edition ...
Cancer May 03, 2013 | 5 / 5 (2) | 0 |
A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs togeth ...
Cancer Jan 08, 2013 | 5 / 5 (1) | 0 |
(Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients ...
Cancer Nov 14, 2012 | 5 / 5 (2) | 0 |
A team of UC Davis scientists has shown in experimental mouse models that a new drug delivery system allows for administration of three times the maximum tolerated dose of a standard drug therapy for advanced bladder cancer, ...
Cancer Oct 25, 2012 | not rated yet | 0 |
(HealthDay) -- Even in the field of cancer treatment, sometimes newer isn't necessarily better.
Cancer Jun 04, 2012 | not rated yet | 0 |
The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an ...
Cancer Jun 04, 2012 | not rated yet | 0 |
(HealthDay) -- Meta-analysis of randomized clinical trials (RCTs) suggests that drug-eluting stents (DESs) significantly reduce repeat revascularizations, with no increase in stent thrombosis (ST), mortality, ...
Cardiology Apr 04, 2012 | 4 / 5 (1) | 0 |
(HealthDay) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting ...
Cardiology Mar 23, 2012 | not rated yet | 0 |
A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.
Medications Oct 06, 2011 | 5 / 5 (2) | 0 |
(Medical Xpress) -- Blocking key proteins could improve response to a common chemotherapy drug, suggests an Oxford University-led study which used cancer cells grown in the lab.
Cancer Sep 02, 2011 | 5 / 5 (2) | 0 |
(Medical Xpress) -- Study uncovers several compounds that inhibit cancer cell invasion, but also reveals that cancer drug paclitaxel does the opposite -- it promotes cancer metastasis.
Cancer Jul 26, 2011 | not rated yet | 0 |
Faults in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to research at Newcastle University.
Cancer Jun 06, 2011 | not rated yet | 0 |
Today's anticancer drugs often work wonders against malignancies, but sometimes tumors become resistant to the effects of such drugs, and treatment fails. Medical researchers would like to find ways of counteracting such ...
Cancer May 16, 2011 | 5 / 5 (1) | 0 |
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative ...
Cancer Apr 08, 2013 | 5 / 5 (2) | 0
Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April ...
Cancer Apr 02, 2013 | 4 / 5 (1) | 0
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a U.S. National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to paclitaxel and the BMS compound is sold under the trademark TAXOL. In this formulation, paclitaxel is dissolved in Cremophor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane.
Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis.
Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division. Together with docetaxel, it forms the drug category of the taxanes. It was the subject of a notable total synthesis by Robert A. Holton.
While offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. There was originally concern because of the environmental impact of its original sourcing, no longer used, from the Pacific yew. In addition, the assignment of rights, and even the name itself, to Bristol-Myers Squibb were the subject of public debate and Congressional hearings.
For more information about Paclitaxel, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.